Type 2 Diabetes: CHMP recommends empagliflozin for approval
21 March 2014 | By Boehringer Ingelheim
Positive opinion for investigational SGLT2 inhibitor empagliflozin for the treatment of T2D in adults...
List view / Grid view
News
Health Canada approves Biogen Idec’s long-acting alprolix™ therapy for hemophilia B
21 March 2014 | By Biogen Idec
The approval of ALPROLIX is first significant advance in hemophilia B treatment in more than 17 years ...
EMA recommends approval of a locally targeted treatment for ulcerative colitis and Crohn’s disease
21 March 2014 | By The European Medicines Agency
Entyvio (vedolizumab) offers a treatment option for patients who do not respond to standard therapies...
Get the green light for weighing with new analytical balances
21 March 2014 | By METTLER TOLEDO
Take the worry out of weighing with new balances designed to aid compliance and process security...
Abbvie initiates new clinical trial to evaluate humira® (adalimumab) for the treatment of fingernail psoriasis
20 March 2014 | By AbbVie
AbbVie announced the initiation of a pivotal Phase 3 clinical trial that will evaluate the use of HUMIRA® (adalimumab)...
Janssen investigational treatment for schizophrenia shows positive efficacy, delays relapse
20 March 2014 | By Johnson & Johnson
Independent data monitoring committee recommends halting trial and unblinding data based on treatment efficacy...
Novartis introduces Lucentis® in state of the art pre-filled syringe
20 March 2014 | By Novartis
Novartis has announced the launch of the Lucentis® (ranibizumab) pre-filled syringe in Germany, with other markets to follow throughout 2014...
Investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoints in MAGRIT, a phase III non-small cell lung cancer clinical trial
20 March 2014 | By GlaxoSmithKline
GSK will continue the trial in order to assess the third co-primary endpoint, which is disease-free survival in a gene signature positive sub-population...
AstraZeneca proposes appointment of Ann Cairns as Non-Executive Director
20 March 2014 | By AstraZeneca
AstraZeneca announced that Ann Cairns will be proposed to shareholders for election as a Non-Executive Director at the Company’s Annual General Meeting on 24 April 2014...
Pfizer’s investigational vaccine candidate bivalent rLP2086 receives U.S. Food and Drug Administration breakthrough therapy designation for potential prevention of meningococcal B disease
20 March 2014 | By Pfizer Inc.
Pfizer intends to submit biologics license application for bivalent rLP2086 to U.S. Food and Drug Administration by mid-2014...
New data from Phase 3 attain study of Janssen’s once-daily simeprevir compared to telaprevir in treatment-experienced adult patients with genotype 1 chronic hepatitis C
19 March 2014 | By Janssen
Additional Phase 3 data from the QUEST-1, QUEST-2 and PROMISE studies explore potential of simeprevir in genotype 1 hepatitis C patients while new ATTAIN data demonstrate a superior safety profile for simeprevir...
EMA publishes its work programme for 2014
19 March 2014 | By The European Medicines Agency
The European Medicines Agency has published its work programme for 2014...
Sanofi Pasteur allies with SK Chemical Co. of South Korea on pneumococcal conjugate vaccine
19 March 2014 | By Sanofi
A long-term strategic business collaboration to co-develop and commercialize an innovative vaccine against pneumococcal infection to address global public-health needs...
Pfizer launches 2013 integrated annual review
19 March 2014 | By Pfizer Inc
Pfizer Inc. announced the launch of its fourth integrated annual review, which summarizes the company’s 2013 financial, environmental and social responsibility performance...
Astellas Pharma and Daiichi Sankyo form compound library sharing partnership
19 March 2014 | By Daiichi Sankyo Company
Astellas Pharma Inc. and Daiichi Sankyo Company, Limited announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds...
